 |
|
|
REFERENCES
1051.
Fukudome T, Ohno K, Brengman JM, et al: Quinidine
normalizes the open duration of slow-channel mutants of the acetylcholine receptor.
Neuroreport 9:1907–1911, 1998.
1052.
Ohno K, Wang HL, Milone M, et al: Congenital
myasthenic syndrome caused by decreased agonist binding affinity due to a mutation
in the acetylcholine receptor epsilon subunit. Neuron 17:157–170, 1996.
1053.
Milone M, Wang HL, Ohno K, et al: Mode switching
kinetics produced by a naturally occurring mutation in the cytoplasmic loop of the
human acetylcholine receptor epsilon subunit. Neuron 20:575–588, 1998.
1054.
Baraka A: Onset of neuromuscular block in myasthenic
patients. Br J Anaesth 69:227–228, 1992.
1055.
Abel M, Eisenkraft JB: Anesthetic implications
of myasthenia gravis. Mt Sinai J Med 69:31–37, 2002.
1056.
Nishino T: Swallowing as a protective reflex
for the upper respiratory tract. Anesthesiology 79:588–601, 1993.
1057.
Cohen MS, Younger D: Aspects of the natural
history of myasthenia gravis: Crisis and death. Ann N Y Acad Sci 377:670–677,
1981.
1058.
Naguib M, el Dawlatly AA, Ashour M, et al:
Multivariate determinants of the need for postoperative ventilation in myasthenia
gravis. Can J Anaesth 43:1006–1013, 1996.
1059.
Eisenkraft JB, Book WJ, Mann SM, et al: Resistance
to succinylcholine in myasthenia gravis: A dose-response study. Anesthesiology
69:760–763, 1988.
1060.
Baraka A: Suxamethonium block in the myasthenic
patient. Correlation with plasma cholinesterase. Anaesthesia 47:217–219,
1992.
1061.
Seigne RD, Scott RP: Mivacurium chloride and
myasthenia gravis. Br J Anaesth 72:468–469, 1994.
1062.
Baraka A: Anaesthesia and myasthenia gravis.
Can J Anaesth 39:476–486, 1992.
1063.
Smith CE, Donati F, Bevan DR: Cumulative dose-response
curves for atracurium in patients with myasthenia gravis. Can J Anaesth 36:402–406,
1989.
1064.
Eisenkraft JB, Book WJ, Papatestas AE: Sensitivity
to vecuronium in myasthenia gravis: A dose-response study. Can J Anaesth 37:301–306,
1990.
1065.
De Haes A, Proost JH, De Baets MH, et al: Pharmacokinetic-pharmacodynamic
modeling of rocuronium in case of a decreased number of acetylcholine receptors:
A study in myasthenic pigs. Anesthesiology 98:133–142, 2003.
1066.
Nilsson E, Meretoja OA: Vecuronium dose-response
and maintenance requirements in patients with myasthenia gravis. Anesthesiology
73:28–32, 1990.
1067.
Kim JM, Mangold J: Sensitivity to both vecuronium
and neostigmine in a sero-negative myasthenic patient. Br J Anaesth 63:497–500,
1989.
1068.
Nilsson E, Paloheimo M, Muller K, et al: Halothane-induced
variability in the neuromuscular transmission of patients with myasthenia gravis.
Acta Anaesthesiol Scand 33:395–401, 1989.
1069.
Nilsson E, Muller K: Neuromuscular effects
of isoflurane in patients with myasthenia gravis. Acta Anaesthesiol Scand 34:126–131,
1990.
1070.
Rowbottom SJ: Isoflurane for thymectomy in
myasthenia gravis. Anaesth Intensive Care 17:444–447, 1989.
1071.
Akpolat N, Tilgen H, Gursoy F, et al: Thoracic
epidural anaesthesia and analgesia with bupivacaine for transsternal thymectomy for
myasthenia gravis. Eur J Anaesthesiol 14:220–223, 1997.
1072.
D'Angelo R, Gerancher JC: Combined spinal and
epidural analgesia in a parturient with severe myasthenia gravis. Reg Anesth Pain
Med 23:201–203, 1998.
1073.
de Jose Maria B, Carrero E, Sala X: Myasthenia
gravis and regional anaesthesia. Can J Anaesth 42:178–179, 1995.
1074.
Small S, Ali HH, Lennon VA, et al: Anesthesia
for an unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult
small cell lung carcinoma. Anesthesiology 76:142–145, 1992.
1075.
Brown JC, Charlton JE: A study of sensitivity
to curare in myasthenic disorders using a regional technique. J Neurol Neurosurg
Psychiatry 38:27–33, 1975.
1076.
Telford RJ, Hollway TE: The myasthenic syndrome:
Anaesthesia in a patient treated with 3,4 diaminopyridine. Br J Anaesth 64:363–366,
1990.
1077.
Newsom-Davis J, Mills KR: Immunological associations
of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature
review. Brain 116(Pt 2):453–469, 1993.
1078.
Vincent A: Understanding neuromyotonia. Muscle
Nerve 23:655–657, 2000.
1079.
Arimura K, Sonoda Y, Watanabe O, et al: Isaacs'
syndrome as a potassium channelopathy of the nerve. Muscle Nerve Suppl 11:S55–S58,
2002.
1080.
Lee EK, Maselli RA, Ellis WG, et al: Morvan's
fibrillary chorea: A paraneoplastic manifestation of thymoma. J Neurol Neurosurg
Psychiatry 65:857–862, 1998.
1081.
Hart IK, Waters C, Vincent A, et al: Autoantibodies
detected to expressed K+
channels are implicated in neuromyotonia. Ann
Neurol 41:238–246, 1997.
1082.
Lang B, Vincent A: Autoimmunity to ion-channels
and other proteins in paraneoplastic disorders. Curr Opin Immunol 8:865–871,
1996.
1083.
Zisfein J, Sivak M, Aron AM, et al: Isaacs'
syndrome with muscle hypertrophy reversed by phenytoin therapy. Arch Neurol 40:241–242,
1983.
1084.
van den Berg JS, van Engelen BG, Boerman RH,
et al: Acquired neuromyotonia: Superiority of plasma exchange over high-dose intravenous
human immunoglobulin. J Neurol 246:623–625, 1999.
1085.
Ashizawa T, Butler IJ, Harati Y, et al: A dominantly
inherited syndrome with continuous motor neuron discharges. Ann Neurol 13:285–290,
1983.
1086.
Hosokawa S, Shinoda H, Sakai T, et al: Electrophysiological
study on limb myokymia in three women. J Neurol Neurosurg Psychiatry 50:877–881,
1987.
1087.
Morgan PJ: Peripartum management of a patient
with Isaacs' syndrome. Can J Anaesth 44:1174–1177, 1997.
1088.
Shillito P, Molenaar PC, Vincent A, et al:
Acquired neuromyotonia: Evidence for autoantibodies directed against K+
channels of peripheral nerves. Ann Neurol 38:714–722, 1995.
1089.
Sinha S, Newsom-Davis J, Mills K, et al: Autoimmune
aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 1991:75–77,
338.
1090.
Steinmeyer K, Lorenz C, Pusch M, et al: Multimeric
structure of ClC-1 chloride channel revealed by mutations in dominant myotonia congenita
(Thomsen). EMBO J 13:737–743, 1994.
1091.
Jurkat-Rott K, Lehmann-Horn F: Human muscle
voltagegated ion channels and hereditary disease. Curr Opin Pharmacol 1:280–287,
2001.
1092.
Mitchell MM, Ali HH, Savarese JJ: Myotonia
and neuromuscular blocking agents. Anesthesiology 49:44–48, 1978.
1093.
Heiman-Patterson T, Martino C, Rosenberg H,
et al: Malignant hyperthermia in myotonia congenita. Neurology 38:810–812,
1988.
1094.
Lehmann-Horn F, Iaizzo PA: Are myotonias and
periodic paralyses associated with susceptibility to malignant hyperthermia? Br
J Anaesth 65:692–697, 1990.
1095.
Ellis FR: Inherited muscle disease. Br J Anaesth
52:153–164, 1980.
1096.
Arcas M, Sanchez-Ortega JL, Garcia-Munoz M,
et al: Anesthesia for cesarean delivery in a case of myotonia congenita [in Spanish].
Rev Esp Anesthesiol Reanim 43:147–149, 1996.
1097.
Cannon SC: Sodium channel defects in myotonia
and periodic paralysis. Annu Rev Neurosci 19:141–164, 1996.
1098.
Ptacek LJ, George AL Jr, Griggs RC, et al:
Identification of a mutation in the gene causing hyperkalemic periodic paralysis.
Cell 67:1021–1027, 1991.
1099.
McClatchey AI, Van den Bergh P, Pericak-Vance
MA, et al: Temperature-sensitive mutations in the III-IV cytoplasmic loop region
of the skeletal muscle sodium channel gene in paramyotonia congenita. Cell 68:769–774,
1992.
1100.
Poskanzer DC, Kerr DNS: A third type of periodic
paralysis, with normokalemia and favourable response to sodium chloride. Am J Med
31:328–342, 1961.
1101.
Meyers KR, Gilden DH, Rinaldi CF, et al: Periodic
muscle weakness, normokalemia, and tubular aggregates. Neurology 22:269–279,
1972.
1102.
Lehmann-Horn F, Rudel R, Ricker K: Non-dystrophic
myotonias and periodic paralyses. A European Neuromuscular Center Workshop held
4–6 October 1992, Ulm, Germany. Neuromuscul Disord 3:161–168, 1993.
1103.
Ashwood EM, Russell WJ, Burrow DD: Hyperkalaemic
periodic paralysis and anaesthesia. Anaesthesia 47:579–584, 1992.
1104.
Flewellen EH, Bodensteiner JB: Anesthetic experience
in a patient with hyperkalemic periodic paralysis. Anesth Rev 7:44, 1980.
1105.
Baur CP, Schara U, Schlecht R, et al: Anesthesia
in neuromuscular disorders. Part 2: Specific disorders [in German]. Anasthesiol
Intensivmed Notfallmed Schmerzther 37:125–137, 2002.
1106.
Moslehi R, Langlois S, Yam I, et al: Linkage
of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal
muscle sodium channel (SCN4A) gene in a large pedigree. Am J Med Genet 76:21–27,
1998.
1107.
Haeseler G, Stormer M, Mohammadi B, et al:
The anesthetic propofol modulates gating in paramyotonia congenita mutant muscle
sodium channels. Muscle Nerve 24:736–743, 2001.
1108.
Haeseler G, Stormer M, Bufler J, et al: Propofol
blocks human skeletal muscle sodium channels in a voltage-dependent manner. Anesth
Analg 92:1192–1198, 2001.
1109.
Weller JF, Elliott RA, Pronovost PJ: Spinal
anesthesia for a patient with familial hyperkalemic periodic paralysis. Anesthesiology
97:259–260, 2002.
1110.
Sternberg D, Maisonobe T, Jurkat-Rott K, et
al: Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the
muscle sodium channel gene SCN4A. Brain 124:1091–1099,
2001.
1111.
Minaker KL, Meneilly GS, Flier JS, et al: Insulin-mediated
hypokalemia and paralysis in familial hypokalemic periodic paralysis. Am J Med 84:1001–1006,
1988.
1112.
Ruff RL: Insulin acts in hypokalemic periodic
paralysis by reducing inward rectifier K+
current. Neurology 53:1556–1563,
1999.
1113.
Shiang R, Ryan SG, Zhu YZ, et al: Mutations
in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic
disorder, hyperexplexia. Nat Genet 5:351–358, 1993.
1114.
Quane KA, Healy JM, Keating KE, et al: Mutations
in the ryanodine receptor gene in central core disease and malignant hyperthermia.
Nat Genet 5:51–55, 1993.
1115.
Rasmussen H, Zawalich KC, Ganesan S, et al:
Physiology and pathophysiology of insulin secretion. Diabetes Care 13:655–666,
1990.
1116.
Osterhoff M, Mohlig M, Schwanstecher M, et al:
Ca(2+)/calmodulin-dependent protein kinase II delta(2) regulates gene expression
of insulin in INS-1 rat insulinoma cells. Cell Calcium 33:175–184, 2003.
1117.
Lehmann-Horn F, Kuther G, Ricker K, et al:
Adynamia episodica hereditaria with myotonia: A non-inactivating sodium current
and the effect of extracellular pH. Muscle Nerve 10:363–374, 1987.
1118.
Siler JN, Discavage WJ: Anesthetic management
of hypokalemic periodic paralysis. Anesthesiology 43:489–490, 1975.
1119.
Lambert C, Blanloeil Y, Horber RK, et al: Malignant
hyperthermia in a patient with hypokalemic periodic paralysis. Anesth Analg 79:1012–1014,
1994.
1120.
Horton B: Anesthetic experiences in a family
with hypokalemic familial periodic paralysis. Anesthesiology 47:308–310, 1977.
1121.
Viscomi CM, Ptacek LJ, Dudley D: Anesthetic
management of familial hypokalemic periodic paralysis during parturition. Anesth
Analg 88:1081–1082, 1999.
1122.
Lofgren A, Hahn RG: Serum potassium levels
after induction of epidural anaesthesia using mepivacaine with and without adrenaline.
Acta Anaesthesiol Scand 35:170–174, 1991.
1123.
Lofgren A, Hahn RG: Hypokalemia from intercostal
nerve block. Reg Anesth 19:247–254, 1994.
1124.
Durfee DD: A practical approach to achieving
a $950,000 cost savings from a joint anesthesia-pharmacy program. Hosp Pharm 30:957–958,
961–963, 1995.
1125.
Gora-Harper ML, Hessel E 2nd, Shadick D: Effect
of prescribing guidelines on the use of neuromuscular blocking agents. Am J Health
Syst Pharm 52:1900–1904, 1995.
1126.
Chiu JW, White PF: The pharmacoeconomics of
neuromuscular blocking drugs. Anesth Analg 90:S19–S23, 2000.
1127.
Souetre EJ, Qing W, Hardens M: Methodological
approaches to pharmaco-economics. Fundam Clin Pharmacol 8:101–107, 1994.
1128.
Horrow JC, Rosenberg H: Price stickers do not
alter drug usage. Can J Anaesth 41:1047–1052, 1994.
1129.
Lin YC, Miller SR: The impact of price labeling
of muscle relaxants on cost consciousness among anesthesiologists. J Clin Anesth
10:401–403, 1998.
1130.
Johnstone RE, Jozefczyk KG: Costs of anesthetic
drugs: Experiences with a cost education trial. Anesth Analg 78:766–771,
1994.
1131.
Gillerman RG, Browning RA: Drug use inefficiency:
A hidden source of wasted health care dollars. Anesth Analg 91:921–924, 2000.
1132.
Ballantyne JC, Chang Y: The impact of choice
of muscle relaxant on postoperative recovery time: A retrospective study. Anesth
Analg 85:476–482, 1997.
1133.
Lubarsky DA, Glass PS, Ginsberg B, et al: The
successful implementation of pharmaceutical practice guidelines. Analysis of associated
outcomes and cost savings. SWiPE Group. Systematic Withdrawal of Perioperative
Expenses. Anesthesiology 86:1145–1160, 1997.
1134.
Freund PR, Bowdle TA, Posner KL, et al: Cost-effective
reduction of neuromuscular-blocking drug expenditures. Anesthesiology 87:1044–1049,
1997.
1135.
Butterworth J, James R, Prielipp RC, et al:
Do shorter-acting neuromuscular blocking drugs or opioids associate with reduced
intensive care unit or hospital lengths of stay after coronary artery bypass grafting?
CABG Clinical Benchmarking Data Base Participants. Anesthesiology 88:1437–1446,
1998.
1136.
Murphy GS, Szokol JW, Marymont JH, et al: Impact
of shorter-acting neuromuscular blocking agents on fast-track recovery of the cardiac
surgical patient. Anesthesiology 96:600–606, 2002.
1137.
Puura AI, Rorarius MG, Manninen P, et al: The
costs of intense neuromuscular block for anesthesia during endolaryngeal procedures
due to waiting time. Anesth Analg 88:1335–1339, 1999.
1138.
Splinter WM, Isaac LA: The pharmacoeconomics
of neuromuscular blocking drugs: A perioperative cost-minimization strategy in children.
Anesth Analg 93:339–344, 2001.
1139.
Miller RD: How should residual neuromuscular
blockade be detected? Anesthesiology 70:379–380, 1989.
1140.
Dexter F, Gan TJ, Naguib M, et al: Cost identification
analysis for succinylcholine. Anesth Analg 92:693–699, 2001.
